# US 2016/0256527 A1 · Tnfrsf-binding agents and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256527 A1
- Document ID: US20160256527A1
- Status: Published application
- Kind: A1
- Application number: 15/014,134
- Filed: 2016-02-03
- Published: 2016-09-08
- Earliest claimed: 2015-02-03
- Assignees: OncoMed Pharmaceuticals, Inc.
- Applicants: OncoMed Pharmaceuticals, Inc.
- Inventors: Austin L. GURNEY
- Web page: https://patentgrep.com/patent/US20160256527A1

## CPC

- A61K 38/19: Cytokines; Lymphokines; Interferons
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K 14/52: Cytokines; Lymphokines; Interferons
- C07K 14/525: Tumour necrosis factor [TNF]
- C07K 14/7151: {for tumor necrosis factor [TNF], for lymphotoxin [LT]}
- C07K 16/18: against material from animals or humans
- C12N 15/00: Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered microorganisms, per se C12N1/00, C12N5/00, C12N7/00; new plants per se A01H; plant reproduction by tissue culture techniques A01H4/00; new animals per se A01K67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K48/00)
- C12N 15/62: DNA sequences coding for fusion proteins
- C12Q 1/68: involving nucleic acids
- A61K 2039/505: {comprising antibodies}
- C07K 2317/31: multispecific
- C07K 2317/55: Fab or Fab'
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Polypeptides and agents that bind a TNF receptor superfamily protein are disclosed, particularly agents that specifically bind GITR, OX40, or CD40. The polypeptides or agents may include fusion polypeptides, particularly polypeptides comprising GITRL, OX40L, or CD40L and/or bispecific agents. Also disclosed are methods of using the polypeptides or agents for inducing and/or enhancing the immune response, as well as methods for the treatment of diseases such as cancer.

## Claims

### Claim at position 1

-213. (canceled)

### Claim 214

A polypeptide comprising a first, second, and third copy of the extracellular domain of a human tumor necrosis factor receptor ligand superfamily (TNFSF) protein or a fragment thereof capable of binding a receptor of the TNFSF protein, wherein at least one of the first, second, or third copies of the extracellular domain or a fragment thereof comprises the stalk region of the TNFSF protein.

### Claim 215 (depends on 214)

The polypeptide of claim 214, wherein the TNFSF protein is selected from the group consisting of glucocorticoid-induced tumor necrosis factor receptor ligand (GITRL), CD40 ligand (CD40L), OX40 ligand (OX40L), 4-1BB ligand, APRIL, BAFF, CD27 ligand, CD30 ligand, EDA, EDA-A1, EDA-A2, Fas ligand, LIGHT, lymphotoxin, lymphotoxin beta, lymphotoxin-alpha, TL1A, TNF-alpha, TRAIL, TRANCE, and TWEAK.

### Claim 216 (depends on 215)

The polypeptide of claim 215, wherein the TNFSF protein is
a) GITRL and the polypeptide comprises SEQ ID NO:5 or SEQ ID NO:66;
b) OX40L and the polypeptide comprises SEQ ID NO:44, SEQ ID NO: 69, SEQ ID NO:70, SEQ ID NO:71, or SEQ ID NO:72; or
c) CD40L and the polypeptide comprises SEQ ID NO:85, or SEQ ID NO:97.

### Claim 217 (depends on 214)

The polypeptide of claim 214, wherein the TNFSF protein is
a) GITRL and the stalk region comprises LQLETAK (SEQ ID NO:32);
b) OX40L and the stalk region is selected from the group consisting of: QVSHRYP (SEQ ID NO:55), ALQVSHRYP (SEQ ID NO:74), SHRYP (SEQ ID NO:75), and HRYP (SEQ ID NO:76); or
c) CD40L and the stalk region is selected from the group consisting of: MQKGDQ (SEQ ID NO:98), FEMQKGDQ (SEQ ID NO:99), EMQKGDQ (SEQ ID NO:100), QKGDQ (SEQ ID NO:101), and KGDQ (SEQ ID NO:102).

### Claim 218 (depends on 216)

The polypeptide of claim 216, which further comprises a human Fc region or an immunoglobulin heavy chain.

### Claim 219 (depends on 218)

The polypeptide of claim 218, wherein the human Fc region is selected from the group consisting of: SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14.

### Claim 220 (depends on 218)

The polypeptide of claim 218, which comprises SEQ ID NO:7.

### Claim 221 (depends on 216)

The polypeptide of claim 216, wherein the TNFSF protein is GITR and which activates GITR and/or induces GITR activity.

### Claim 222 (depends on 214)

The polypeptide of claim 214, which:
(a) increases cell-mediated immunity;
(b) increases T-cell activity;
(c) increases cytolytic T-cell (CTL) activity;
(d) increases natural killer (NK) cell activity;
(e) decreases or inhibits regulatory T-cell (Treg) activity; and/or
(f) decreases or inhibits myeloid-derived suppressor cell (MDSC) activity.

### Claim 223

A polypeptide encoded by the plasmid deposited with ATCC and assigned designation number PTA-122112.

### Claim 224 (depends on 214)

A bispecific agent comprising:
a) the polypeptide of claim 214, and
b) an antigen-binding site from an antibody.

### Claim 225 (depends on 224)

The bispecific agent of claim 224, wherein the agent is a homodimer or a heterodimer.

### Claim 226

A bispecific agent comprising:
a) a first arm comprising a polypeptide comprising a first, second, and third copy of the extracellular domain of a human tumor necrosis factor receptor ligand superfamily (TNFSF) protein or a fragment thereof, and
b) a second arm comprising an antigen-binding site from an antibody.

### Claim 227 (depends on 226)

The bispecific agent of claim 226, wherein the TNFSF protein is GITRL, OX40L, or CD40L.

### Claim 228 (depends on 214)

A pharmaceutical composition comprising the polypeptide of claim 214 and a pharmaceutically acceptable carrier.

### Claim 229 (depends on 214)

A polynucleotide comprising a polynucleotide that encodes the polypeptide of claim 214.

### Claim 230 (depends on 214)

An isolated cell comprising or producing the polypeptide of claim 214.

### Claim 231 (depends on 214)

A method of treating cancer in a subject, a method of inducing, activating, promoting, increasing, enhancing, or prolonging an immune response in a subject, method of inhibiting the growth of a tumor in a subject, method of increasing T-cell activity in a subject, method of increasing cytolytic T-cell (CTL) activity in a subject, method of increasing natural killer (NK) activity in a subject, method of decreasing or inhibiting regulatory T-cell (Treg) activity in a subject, or a method of decreasing or inhibiting myeloid-derived suppressor cell (MDSC) activity in a subject, comprising administering to a subject a therapeutically effective amount of the polypeptide of claim 214.

### Claim 232 (depends on 231)

The method of claim 231, wherein the cancer is selected from the group consisting of colorectal cancer, colon cancer, ovarian cancer, pancreatic cancer, lung cancer, liver cancer, breast cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, head and neck cancer, lymphoma and leukemia.

### Claim 233 (depends on 231)

The method of claim 231, which further comprises administering at least one additional therapeutic agent.

### Claim 234 (depends on 233)

The method of claim 233, wherein the additional therapeutic agent is a chemotherapeutic agent or an agent that stimulates the immune response.

### Claim 235 (depends on 233)

The method of claim 233, wherein the additional therapeutic agent is an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CTLA-4 antibody, or an anti-TIGIT antibody.

### Claim 236

A method of decreasing or inhibiting regulatory T-cell (Treg) activity or myeloid-derived suppressor cell (MDSC) activity in a subject, or a method of increasing T-cell activity, cytolytic T-cell (CTL) activity, or natural killer (NK) activity in a subject, comprising administering to the subject a therapeutically effective amount of a polypeptide comprising a first, second, and third copy of the extracellular domain of a human tumor necrosis factor receptor ligand superfamily (TNFSF) protein or a fragment thereof capable of binding a receptor of the TNFSF protein.

### Claim 237 (depends on 236)

A method of claim 236, wherein the TNFSF protein is GITRL, OX40L, or CD40L.
